Figure 7 shows that in the various serum concentrations, myostatin was over-expressed by ZFS in the ZF4-SC versus C, and in the ZL4-SC, albeit to a lesser extent under 2.5% and 1% ZFS. The 1% ZLS concentration was unexpectedly as effective as ZFS, suggesting a basal, unspecific effect of rat serum unrelated to dyslipidemia. In addition to the similarity of ZF4-SC and ED-MDSC responses, this was concordant with ZFS down-regulation of miRs known to counteract myostatin in Table 2. The gene discussed is MSTN; the disease is metabolic syndrome.